Beyond Biotech - the podcast from Labiotech

Immunology is a key area in biotech and biopharma, both in terms of R&D and sales.

However, according to UK-headquartered Greywolf Therapeutics, the industry has only focused on two-thirds of the puzz…

The Bill & Melinda Gates Medical Research Institute (Gates MRI) is a non-profit medical research organization dedicated to the development and effective use of products like drugs, vaccines and monoc…

This week, we are taking a look at an important subject, and that is women working as CEOs, or other senior roles, in the biotech space. 

Kate Yen is the CEO of oncology biotech Auron Therapeutics, an…

Sitryx Therapeutics is a private UK biopharma company founded in 2018. It is a leader in the field of immunometabolism, an area of immunology that looks to rebalance the immune system to achieve sust…

LinkGevity, founded by two sisters, is developing anti-necrotic technologies, especially for application in kidney disease.

Carina Kern is the CEO of the company, while Serena Kern-Libera is the chief…

Today, gene therapy is at an exciting inflection point as the industry moves beyond the first generation of these therapies. However, challenges and barriers remain in bringing gene therapies to mark…

Antibody-drug conjugates have been an area of great interest in the oncology space in recent years, with a record rate of FDA approvals and dealmaking activity. However balancing efficacy and off-sit…

Telomeres are structures made from DNA sequences and proteins, and they are found at the ends of chromosomes.

In effect, they cap and protect the end of a chromosome. Telomerase is an enzyme that add…

C4 Therapeutics (C4T) is a leader in the targeted protein degradation (TPD) field, with two oncology drug candidates currently in clinical trials and collaborations with pharma companies like Merck, …

Estonia is working on becoming the first country to implement personalized health at scale through the Estonian National Biobank.

The biobank uses genetic data to create a picture of the Estonian popu…

Inflammation appears to affect almost every part of the human body as we age, including cancer, type-2 diabetes, obesity, and neurodegenerative disorders.

NLRP3 inflammasome-induced inflammation is at…

Tumor infiltrating lymphocyte (TIL) therapy uses a person’s own immune cells to fight advanced melanoma, offering new hope for patients who have limited treatment options. 

This week, we have a conver…

The development of combination vaccines could represent a significant advancement in the fight against infectious diseases. With the potential to streamline the vaccination process and provide broade…

Pentixapharm is a clinical-stage radiopharmaceutical development company targeting a range of diseases. 

While it is currently owned by the Eckert & Ziegler Group, it will soon be spun off as a separa…

There are many questions when it comes to setting up a biotech company, and raising funds.

Currently, many companies are concerned about fundraising, but there are things that can be done to maximize…

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer!

Epic Bio is an …

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer!

Artificial inte…

Aurion Biotech is a US biotech with a regenerative medicine platform, developing novel therapies to restore vision to millions of people in need. 

This week on the podcast, we have a conversation with…

LabGenius is a drug discovery company developing next-generation therapeutic antibodies.  

The company’s discovery platform, EVA, integrates several technologies drawn from the fields of artificial in…

Acute on-chronic liver failure (ACLF) is a significant healthcare issue with high unmet needs for patients and clinicians, and a massive burden for healthcare systems. It cost more than $6bn in the U…